CAM
MRTX

ClariVest Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

ClariVest Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,322
Closed -$375K – 842
2021
Q2 		$375K Buy
2,322
+7
+0.3% +$1.12K 0.01% 456
2021
Q1 		$396K Sell
2,315
-100
-4% -$19.8K 0.01% 446
2020
Q4 		$530K Sell
2,415
-3,108
-56% -$672K 0.02% 367
2020
Q3 		$917K Buy
+5,523
New +$756K 0.03% 310

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClariVest Asset Management's MRTX Position: Q3 2021 in Review

ClariVest Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 2,322 shares — an estimated $375K sold.

ClariVest Asset Management first reported a position in MRTX in Q3 2020 and held it in 4 quarters. The position peaked at $917K in Q3 2020. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

  • ClariVest Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 2,322 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $375K.
  • ClariVest Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • ClariVest Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $917K in Q3 2020.
  • 238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on ClariVest Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.